Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by t…
The bill (Prescription Drug Transparency and Affordability Act) requires pharmacy benefit managers (PBMs) and related entities to produce standardized, frequent reports to group health plans and issuers.
Reports must include detailed drug‑level claims, compensation, rebates, net prices, dispensing channel data, affiliated pharmacy pricing, formulary rationales for high‑cost drugs, and participant summary documents.
It applies across the Public Health Service Act, ERISA, and the Internal Revenue Code, includes privacy protections aligned with HIPAA, sets enforcement penalties for noncompliance or false information, and tasks the Secretary with rulemaking and format standards.
Content aligns with common transparency reforms and contains compromise features, but heavy complexity and entrenched industry interests make enactment uncertain.
Relative to its intended legislative type, this bill is a substantive statutory reform that is drafted with high precision in terms of obligations, data elements, definitions, enforcement authority, and inter‑statutory alignment. It creates new, concrete duties on plans, issuers, and entities providing pharmacy benefit management services, backed by penalties and rulemaking deadlines.
Liberals focus on accountability and downstream price reforms
Liberals focus on accountability and downstream price reforms
Generally supportive; sees the bill as increasing transparency into PBM rebate flows and conflicts of interest.
Views this reporting as a necessary step toward lowering drug costs, though stronger direct price or rebate‑pass‑through measures might still be needed.
Cautiously supportive; welcomes standardized data and participant access but worries about administrative burden, trade‑secret litigation, and whether reporting will meaningfully lower costs.
Prefers careful rulemaking, phased implementation, and cost‑benefit analysis.
Skeptical; views extensive federal reporting mandates as regulatory overreach into private contracts and markets.
Concerned about burdens on businesses, exposure of proprietary information, and heavy civil penalties, though might accept narrow transparency for large plans.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content aligns with common transparency reforms and contains compromise features, but heavy complexity and entrenched industry interests make enactment uncertain.
The bill has not accumulated any surfaced votes yet.
Liberals focus on accountability and downstream price reforms
Content aligns with common transparency reforms and contains compromise features, but heavy complexity and entrenched industry interests ma…
Relative to its intended legislative type, this bill is a substantive statutory reform that is drafted with high precision in terms of obligations, data elements, definitions, enforcement authority, and inter‑statutory…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.